 cost benefit secondari prophylaxi pneumocysti carinii pneumonia object rel cost benefit aerosol pentamidin combin product sulfamethoxazol trimethoprim sulfat secondari prophylaxi pneumocysti carinii pneumonia design markov-bas cost-benefit analysi drug efficaci toxic mortal rate current literatur set hypothet patient popul patient human immunodefici viru episod carinii pneumonia intervent use aerosol pentamidin sole first-lin prophylact agent patient regimen use sulfamethoxazole-trimethoprim patient histori toxic reaction drug patient histori toxic effect toxic effect drug aerosol pentamidin secondari prophylaxi main outcom measur net cost median patient surviv surviv regimen regimen regimen main result domin net cost patient median surviv year prophylaxi regimen save patient increas median surviv regimen regimen save increas median surviv conclus secondari prophylaxi carinii money surviv current data suggest sulfamethoxazole-trimethoprim use aerosol pentamidin first-lin agent modest increas cost decreas life expect